Quantification of BCR-ABL mRNA in plasma/serum of patients with chronic myelogenous leukemia

International Journal of Medical Sciences

Volumn 9, Issue 10, 2012, Pages 901-908

  Narita, Miwako ^a   Saito, Anri ^a   Kojima, Aya ^a   Iwabuchi, Minami ^a   Satoh, Naoya ^a   Uchiyama, Takayoshi ^a   Yamahira, Akie ^a   Furukawa, Tatsuo ^b   Sone, Hirohito ^c   Takahashi, Masuhiro ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^c NIIGATA UNIVERSITY   (Japan)

Author keywords

BCR ABL; CML; mRNA; Plasma; Real time RT PCR; Serum; WT1

Indexed keywords

BCR ABL PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA;

ARTICLE; BLOOD CELL; CENTRIFUGATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; KARYOTYPE; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA DEGRADATION; RNA EXTRACTION; TUMOR VOLUME;

BCR-ABL; CML; MRNA; PLASMA; REAL-TIME RT-PCR.; SERUM; WT1;

AGED; FUSION PROTEINS, BCR-ABL; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PLASMA; RNA, MESSENGER; SERUM; WT1 PROTEINS;

EID: 84869430425     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.4655     Document Type: Article

References (21)

1. Ma W, Tseng R, Gorre M, et al. Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia. Haematologica. 2007;92:170-5.
2. Silva JM, Dominguez G, Silva J, et al. Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clinical cancer research: an official journal of the American Association for Cancer Research. 2001;7:2821-5.
3. El-Hefnawy T, Raja S, Kelly L, et al. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clinical chemistry. 2004;50:564-73.
4. Kamm RC, Smith AG. Nucleic acid concentrations in normal human plasma. Clinical chemistry. 1972;18:519-22.
5. Stroun M, Anker P, Maurice P, et al. Circulating nucleic acids in higher organisms. International review of cytology. 1977;51:1-48.
6. Kamm RC, Smith AG. Ribonuclease activity in human plasma. Clinical biochemistry. 1972;5:198-200.
7. Kopreski MS, Benko FA, Kwak LW, et al. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 1999;5:1961-5.
8. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nature reviews Cancer. 2011;11:426-37.
9. Lo KW, Lo YM, Leung SF, et al. Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. Clinical chemistry. 1999;45:1292-4.
10. Chen XQ, Bonnefoi H, Pelte MF, et al. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research. 2000;6:3823-6.
11. Kopreski MS, Benko FA, Gocke CD. Circulating RNA as a tumor marker: detection of 5T4 mRNA in breast and lung cancer patient serum. Annals of the New York Academy of Sciences. 2001;945:172-8.
12. Ng EK, Tsui NB, Lam NY, et al. Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals. Clinical chemistry. 2002;48:1212-7.
13. Hasselmann DO, Rappl G, Tilgen W, et al. Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clinical chemistry. 2001;47:1488-9.
14. Tsui NB, Ng EK, Lo YM. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clinical chemistry. 2002;48:1647-53.
15. Dasi F, Martinez-Rodes P, March JA, et al. Real-time quantification of human telomerase reverse transcriptase mRNA in the plasma of patients with prostate cancer. Annals of the New York Academy of Sciences. 2006;1075:204-10.
16. Kudo Y, Ochi T, Shimada H, et al. Utility of plasma circulating mRNA as a marker to detect hepatic injury. The Journal of veterinary medical science / the Japanese Society of Veterinary Science. 2008;70:993-5.
17. Takahashi S, Miura N, Harada T, et al. Prognostic impact of clinical course-specific mRNA expression profiles in the serum of perioperative patients with esophageal cancer in the ICU: a case control study. Journal of translational medicine. 2010;8:103.
18. Garcia V, Garcia JM, Pena C, et al. Free circulating mRNA in plasma from breast cancer patients and clinical outcome. Cancer letters. 2008;263:312-20.
19. Garcia V, Garcia JM, Silva J, et al. Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications. PloS one. 2009;4:e8173.
20. Kang Y, Zhang J, Sun P, et al. Circulating cell-free human telomerase reverse transcriptase mRNA in plasma and its potential diagnostic and prognostic value for gastric cancer. International journal of clinical oncology / Japan Society of Clinical Oncology. 2012.
21. Ma W, Jilani I, Gorre M, et al. Plasma as a source of mRNA for determining IgV(H) mutation status in patients with chronic lymphocytic leukaemia. Br J Haematol. 2006;133:690-2.